" class="no-js "lang="en-US"> Samsung Biologics - Medtech Alert
Thursday, March 28, 2024
Samsung Biologics | Pharmtech Focus

Samsung Biologics

About Samsung Biologics

Samsung Biologics

Samsung Biologics is a fully integrated CDMO offering state-of-the-art contract development, manufacturing, and laboratory testing services. With proven regulatory approvals, the largest capacity at a single site, and the fastest throughput, Samsung Biologics is an award-winning partner of choice and is uniquely able to support the development and manufacturing of biologics products at every stage of the process while meeting the evolving needs of biopharmaceutical companies worldwide.

Related Story

Samsung Biologics Reaches Agreement with Biogen to Acquire Full Ownership of Samsung Bioepis

January 28 2022

Samsung Biologics (KRX: 207940.KS) announced today that it has reached an agreement with Biogen for the buyout […]

GreenLight Biosciences and Samsung Biologics announce collaboration to build capacity for messenger RNA Vaccine Manufacturing

November 24 2021

GreenLight Biosciences (Nasdaq: ENVI), a biotechnology company dedicated to making ribonucleic acid (RNA) products affordable and […]

Samsung Biologics to Add mRNA Vaccine Drug Substance Manufacturing Suite to Expand Portfolio of Services

June 1 2021

Samsung Biologics (KRX: 207940.KS), a leading global CDMO providing end-to-end contract development and manufacturing services, […]